The following new and competitive renewal grants and awards were recorded in the Office of Grants Management for July 1999.
"Biochemistry/Molecular Biology of OP-1," Dr. John Lee, Stryker Biotech, $662,400, 2 years.
Cellular & Structural Biology
"Virologic & Immunologic Studies of Murine CMV Retinitis," Dr. Sally Atherton, National Institutes of Health (NIH)/National Eye Institute (NEI), $60,000, 1 year.
"Selecting New Coding Sequences by PCR with CDNA Primers," Dr. Pudur Jagadeeswaran, NIH/Kalgen Inc., $125,078, 1 year.
Dean, Nursing School
"Professional Nurse Traineeship Program," Dr. Janet Allan, Department of Health & Human Services (DHHS)/Health Resources & Services Administration (HRSA), $43,498, 1 year.
"Mexican-American Infant Feeding Beliefs," Dr. Sara Gill, Texas Department of Health, $4,075, 3 months.
"Nurse Practitioner & Nurse Midwifery Program," Dr. Judith Longworth, DHHS/HRSA, $302,450, 1 year.
"Environmental House Calls," Dr. Claudia Miller, The National Environmental Education & Training Foundation Inc., $15,000, 1 year.
Institute of Biotechnology
"Multicorn as an Example of Regulation of Proteolytic Activities of Large Complexes on a Molecular Level," Dr. Maria Gaczynska, National Science Foundation, $389,260, 2 years.
"Cancer Suppression by the Retinoblastoma Gene," Dr. Wen-Hwa Lee, NIH/National Cancer Institute (NCI), $1,038,784, 9 months.
"Host Genetic Determinants of HIV Pathogenesis," Dr. Sunil Ahuja, NIH/National Institute of Allergy & Infectious Diseases (NIAID), $643,363, 1 year.
"Intergovernmental Personnel Act Agreement for Jerry Alan Bates," Dr. Robert Clark, South Texas Veterans Health Care System, $54,247, 2 years.
"Development of Pressure, Volume Relationships in Small Animal Hearts," Dr. Marc Feldman, Millar Instruments Inc., $26,300, 1 year.
"Randomized, Controlled Trial of SCH 56592 Oral Suspension vs. Fluconazole Suspension in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients," Dr. John Graybill, Schering-Plough Research Institute, $29,571, 2 years.
"Primary Care Residency Program," Dr. Mark Henderson, Texas Higher Education Coordinating Board, $45,000, 1 year.
"Study of Intravenous Immunoglobulin in Generalized Myasthenia Gravis," Dr. Carlayne Jackson, University of Texas Southwestern Medical Center at Dallas, $9,259, 1 year, 8 months.
"Targeted Antibody Inhibition of Bone Metastases by Prostate Cancer," Dr. Xiaochun Li, Department of the Army, $83,642, 2 years.
"Effects of Tumors on the Skeleton," Dr. Gregory Mundy, NIH/NCI, $5,355,647, 5 years.
"A Double-Blind, Randomized, Multicenter Trial Comparing the Efficacy & Tolerability of 250 MG of Faslodex with 20 MG of Nolvadex in Postmenopausal Women with Advanced Breast Cancer," Dr. Peter Ravdin, Zeneca Pharmaceuticals, $67,997, 1 year.
"Evaluation of Photo-oxidative Stress in H-Tert Transfected Cells," Dr. Randolph Glickman, Geron Corporation, $33,993, 5 months.
"Characterization of Wear Debris Produced at Sulzer Orthopaedics," Dr. Mauli Agrawal, Sulzer Orthopaedics Inc., $30,000, 1 year.
"Clinical Utility of EBV Viral-Load Assays in HIV Patients," Dr. Margaret Gulley, Cancer Therapy & Research Center, $42,709, 1 year.
"Biomarkers of Clinical Outcome in Nasopharyngeal Carcinoma," Dr. Margaret Gulley, Cancer Therapy & Research Center, $40,296, 1 year.
"GPS-014/QDA FDA Clinical Susceptibility Study," Dr. James Jorgensen, Biomerieux Vitek, $14,000, 6 months.
"Analytic Laboratory Agreement," Dr. Michael Rinaldi, Novartis Consumer Health Inc., $89,900, 1 year.
"HIV Pediatric Surveillance," Dr. Victor German, Texas Department of Health, $1,276, 1 year.
"A Randomized, Comparative Study of Alatrofloxacin vs. Centriaxone with Optional Vancomycin in Children with Bacterial Meningitis," Dr. Hal Jenson, Pfizer Inc., $24,000, 1 year.
"Texas Genetics Network," Dr. Celia Kaye, Texas Department of Health, $39,489, 1 year.
"Analytical & Pharmacokinetic Analysis of MGI 114," Dr. John Kuhn, MGI Pharma, $38,024, 1 year.
"A Randomized, Double-Blind, Amlodipine & Losartan-Controlled Study of Omapatrilat in Subjects with Mild to Moderate Hypertension," Dr. Alexander Shepherd, Bristol Myers Squibb, $29,855, 6 months.
"Program for Minority Research Training in Psychiatry," Dr. Charles Bowden, American Psychiatric Association, $33,012, 1 year.
"Technical Services for Psychotherapeutic Drug Levels," Dr. Martin Javors, University Health System, $3,600, 1 year.
"The Texas Approach to Psychosocial Rehabilitation Plan," Dr. Delia Saldana, Texas Department of Mental Health & Mental Retardation, $50,000, 2 years.
"The Texas Approach to Psychosocial Rehabilitation Plan," Dr. Delia Saldana, Texas Department of Mental Health & Mental Retardation, $2,000, 2 years.
"DNA-Damaging Agents & Apoptosis in Prostate Cancer," Dr. Barbara Woynarowska, NIH/NCI, $546,575, 4 years.
"A Randomized, Controlled Study to Evaluate the Role of an In-Home Asthma Disease Management Program Provided by Respiratory Therapists in Improving Outcomes & Reducing the Cost of Care," Dr. Terry Legrand, American Association for Respiratory Care, $115,378, 2 years.
"Pell Grant Program," Dr. Robert Lawson, Department of Education, $446,126, 1 year.
"Educational Support for the Portland Bone Symposium" Dr. John Schmitz, NIH/National Institute of Dental & Craniofacial Research (NIDCR), $9,375, 1 year.
MERIT honoree heads team studying gene therapy for kidney inflammation Dr. Hanna Abboud, professor of medicine and chief of the Nephrology Division, is seeking genetic keys to slow or even reverse kidney damage. His research findings soon may help those who are susceptible to renal disease, freeing them from the threat of kidney failure and the confinement of blood-filtering dialysis treatments.
Dr. Abboud is one of about 10 Health Science Center researchers who hold the prestigious MERIT designation from the National Institutes of Health (NIH). MERIT, which stands for "Method to Extend Research in Time," provides long-term, stable support for an investigator's research program. Dr. Abboud's lab team is studying potential gene therapy for glomerulonephritis, which is inflammation of the capillaries or small blood vessels in the kidney.
In addition to receiving the MERIT Award in 1998, Dr. Abboud's team captured a highly competitive Research Enhancement Award from the U.S. Department of Veterans Affairs. Only two renal research programs received this funding nationwide; the other program is in South Carolina. Dr. Abboud is the principal investigator on this grant, which brought support of more than $1.3 million to the Health Science Center and matching funds in the same amount to the South Texas Veterans Health Care System.
Co-investigators on the "Gene Therapy for Glomerulonephritis" grant are Drs. Dan Riley, Jeffrey Barnes, Sherry Abboud, Balakuntalam Kasinath and Goutam Ghosh-Choudhury, all from the Department of Medicine.
The researchers have identified several signaling molecules involved in the progression of kidney inflammation. This inflammation, called glomerulonephritis, results in about one-third of all cases of end-stage renal disease. Patients with this severity of disease must undergo dialysis treatment regularly to remove waste products from their bodies. Currently the damage is irreversible. The scientists hope to find gene therapies to halt the inflammation process and prevent end-stage renal disease.
Dr. Abboud and his colleagues plan to study experimental models of renal disease (mice and rats) investigating ways to neutralize the effect of the culprit molecules. "We want to knock out action at specific points in inflammation pathways," he said. The result may be a significant breakthrough in the prevention and treatment of kidney disease.